Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617001565336
Ethics application status
Approved
Date submitted
14/11/2017
Date registered
21/11/2017
Date last updated
14/07/2024
Date data sharing statement initially provided
14/07/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
Comparative assessment of the absorption of a generic formulation of mesalazine tablet against the innovator mesalazine tablet conducted under fasting conditions in healthy male and female volunteers
Scientific title
A single dose, randomized, blinded, bioequivalence study of a test formulation of mesalazine tablet in a 3 way crossover comparison against the innovator mesalazine tablet conducted under fasting conditions in healthy male and female volunteers
Secondary ID [1] 293362 0
None
Universal Trial Number (UTN)
U1111-1202-0175
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bioequivalence study conducted in healthy volunteers comparing two formulations of mesalazine tablet with no health condition or problem studied.

Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, mezalazine is used for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis. 305482 0
Condition category
Condition code
Oral and Gastrointestinal 304737 304737 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Single dose, three sequence, crossover study design whereby each participant receives the test formulation of mesalazine oral tablet (1 x 1.2 g) on one occasion and the innovator formulation of mesalazine oral tablet (1 x 1.2 g) on two occasions with each dose seperated by a one week washout period. The intervention for this trial is the test formulation of mesalazine.

No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with the dose).

Participants are required not to eat for 10 hours prior to dosing. Subjects are required to fast for approximately 4 hours after receiving each dose. Bathroom visits will be supervised to ensure no unauthorised water or food intake and for personal safety. Participants will be confined at the Clinical Site for 10 hours prior to dosing to ensure compliance and will be monitored for adverse events for 24 hours after dosing.

Standard meals will be consumed at the Clinical Site with no additional food intake allowed. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site 10 hours prior to dosing.

Pre and post study laboratory tests will be completed to assess the health of participants along with HIV, Hepatitis and drugs of abuse testing.

Each dose will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure the medication has been taken as directed.
Intervention code [1] 299619 0
Treatment: Drugs
Comparator / control treatment
Single dose, crossover study design whereby each participant receives the test formulation of mesalazine (1 x 1.2 g) on one occasion and the innovator formulation of mesalazine (1 x 1.2 g) on two occasions with each dose seperated by a one week washout period. The comparator/control for this trial is the innovator formulation of mesalazine.
Control group
Active

Outcomes
Primary outcome [1] 303951 0
To compare the bioavailability of mesalazine (as summarised by Cmax and AUC) for the formulation. All plasma samples will be assayed for mesalazine using one fully validated LC/MS/MS method. Validation will be conducted to comply with EU and FDA guidelines.
Timepoint [1] 303951 0
0 (pre-dose), 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 11, 12, 16, 20, 24, 28, 36, 48, 56 and 72 hours post dosing.
Secondary outcome [1] 340529 0
Time to maximum peak concentration (Tmax) will be determined by plasma sample analysis. Tmax will be the time where the maximum concentration occurred in the sample points.
Timepoint [1] 340529 0
0 (pre-dose), 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 11, 12, 16, 20, 24, 28, 36, 48, 56 and 72 hours post dosing.

Eligibility
Key inclusion criteria
Healthy male and non-pregnant females
Aged between 18 and 55
Non-smoker
BMI between 18 and 33 inclusive
Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
Able to provide written informed consent
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
Concomitant drug therapy of any kind
Sensitivity to the study drug
History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
Females who are pregnant and/or are breastfeeding
Smoker (anyone who has smoked in the last 6 months)
History of alcohol or drug abuse or dependency
Participation in a drug study within 60 days of the start of the study or donated blood in the 60 days preceding the study.
Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All formulations will be labelled as Formulation A and B. The identification of each treatment will only be known to the Managing Director and the Section Head - Trials and Regulatory Affairs.

Each participant will be identified by a 3 digit screening number and a 2 digit subject number. The screening number will be issued once the participant has given written consent to participate in the study and the two digit subject number (randomisation number) after acceptance into the study. Sequence generation will be by using a simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation).
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation list will be prepared using a computer program for a partial replicate, reference scaled three-way crossover design.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Bio-equivalence
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
28/11/2017
Actual
5/12/2017
Date of last participant enrolment
Anticipated
Actual
17/02/2018
Date of last data collection
Anticipated
Actual
20/02/2018
Sample size
Target
36
Accrual to date
Final
34
Recruitment outside Australia
Country [1] 9358 0
New Zealand
State/province [1] 9358 0
Otago

Funding & Sponsors
Funding source category [1] 297984 0
Commercial sector/Industry
Name [1] 297984 0
Southern Cross Pharma Pty Ltd
Country [1] 297984 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Zenith Technology Corp Ltd
Address
156 Frederick St
Dunedin 9016
Country
New Zealand
Secondary sponsor category [1] 297052 0
None
Name [1] 297052 0
Address [1] 297052 0
Country [1] 297052 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 299025 0
Central Health and Disability Ethics Committee
Ethics committee address [1] 299025 0
Ethics committee country [1] 299025 0
New Zealand
Date submitted for ethics approval [1] 299025 0
13/09/2017
Approval date [1] 299025 0
11/10/2017
Ethics approval number [1] 299025 0
17/CEN/190

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 79030 0
Dr Noelyn Hung
Address 79030 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 79030 0
New Zealand
Phone 79030 0
+6434779669
Fax 79030 0
+6434779605
Email 79030 0
[email protected]
Contact person for public queries
Name 79031 0
Linda Folland
Address 79031 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 79031 0
New Zealand
Phone 79031 0
+6434779669
Fax 79031 0
+6434779605
Email 79031 0
[email protected]
Contact person for scientific queries
Name 79032 0
Tak Hung
Address 79032 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 79032 0
New Zealand
Phone 79032 0
+6434779669
Fax 79032 0
+6434779605
Email 79032 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
All data will be compiled into a final report that is the property of the sponsor company. All participant data will be provided in summary format and result of the study only will be reported.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.